Alyssa Levin
Director of Finance/CFO bij NKARTA, INC.
Vermogen: 605 360 $ op 31-03-2024
Actieve functies van Alyssa Levin
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| NKARTA, INC. | Director of Finance/CFO | 05-07-2023 | - |
Loopbaan van Alyssa Levin
Eerdere bekende functies van Alyssa Levin
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Director of Finance/CFO | - | 05-07-2023 |
Opleiding van Alyssa Levin
| University of British Columbia | Undergraduate Degree |
| Edwards School of Business | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Canada | 3 |
Operationeel
| Director of Finance/CFO | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NKARTA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Beurs
- Insiders
- Alyssa Levin
- Ervaring
